

# ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## BRAIN SCANNER DEVELOPMENT UPDATE

### Highlights:

- *New headset design with integrated VNA to improve performance*
- *Significant improvements to device architecture for manufacture that will increase reliability, reduce cost, and improve usability.*
- *On track for the first units of EMVision's next generation device, intended for expanded clinical trials and commercialisation, to be fabricated CY Q3 2021.*
- *These units will be the subject of verification and validation testing in preparation for expanded clinical studies.*
- *Additional data collection progressing well at Princess Alexandra Hospital, to inform algorithm enhancement, with an additional 9 stroke patients scanned to date.*

**EMVision Medical Devices Limited (ASX:EMV)** ("EMVision" or the "Company"), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to provide the following product development update. In addition to the incorporation of the VNA into the headset design there have been continued improvements and upgrades to the system design for EMVision's 1<sup>st</sup> generation device intended for commercialisation. This device can be wheeled directly to a patient's bedside, for point of care neuroimaging, whether that patient is in a stroke or neurology ward, an intensive care unit or an emergency department. Bedside imaging is particularly helpful for stroke patients who are critically ill or difficult to transport. The procurement and finalisation of key custom-made materials and parts are well underway for this device, with first units to be fabricated in CY Q3 2021.


Several improvements in product design have been introduced in different areas to address manufacturability, reliability, and performance of the device including but not limited to the antennae, coupling liquid, decoupling media, membrane, shielding and also in the selection of the most appropriate materials from both chemical resistance and bio-compatibility perspectives. The antennas have undergone an improved manufacturing process which increased the yield of antennas in the production line to over 95%. Furthermore, improvement in the decoupling manufacturing process resulted in a cost reduction as well as improvement to system performance. Finally, a new headset membrane has been designed to accommodate the broadest range of the adult population.

Once fabricated these units will be the subject of calibration, verification and validation and electromagnetic compatibility testing in preparation for expanded clinical studies. The EMVision team is working closely with the Australian Stroke Alliance, its regulatory team and clinical collaborators in the planning and preparation for the expanded multi-site clinical studies.


As previously advised, the Company is enrolling an additional 20 stroke patients with the clinical prototype at Princess Alexandra Hospital, to further inform algorithm advancements in parallel with commercial product development activities and expanded clinical study preparation. The enrolment is progressing positively, with an additional 9 stroke patients enrolled to date, taking the total to 39 stroke patient datasets. The Company expects to provide updates to the market as it reaches further relevant milestones throughout clinical testing

## Significant improvement in design to incorporate miniaturised Vector Network Analyser (VNA)

Clinical Prototype



1<sup>st</sup> Gen Device intended for commercialization



The above images show the Clinical Prototype (left) with Vector Network Analyser (VNA) in trolley (highlighted blue) and the 1<sup>st</sup> gen intended for commercialisation device headset (right) with VNA in headset (highlighted blue). The headset now incorporates the miniaturised VNA. The VNA is an integral component of the EMVision system and is responsible for the accurate measurement of signals sent/received within the headset. It has been dramatically miniaturised via EMVision's collaboration with Keysight Technologies (NYSE:KEYS). Cables have been removed in favour of an articulated arm which will connect the headset to a trolley and enables easy headset positioning on the patient.

EMVision CEO, Dr Ron Weinberger, commented “We continue to make good progress while incorporating our learnings from our clinical study and acquired patient datasets. Implementing the miniaturised VNA in the headset is a major leap that not only improves usability but has an eye to the future ambulance version. The expanded team has significantly improved our ability to execute to plan while providing expertise to innovate along the way. Our facility at Macquarie Park, Sydney, is at the centre of a MedTech hub with ready access to world class expertise. We are well positioned to meet our upcoming milestones.”

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Investor Relations  
+61 400 400 800  
andrew.keys@keysthomas.com

Sling & Stone  
Media and Communications  
emvision@slingstone.com  
02 8073 5390

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

### **About EMVision Medical Devices**

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision’s Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision’s CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.6 billion market cap healthcare company. Dr Weinberger has over 25-years’ experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company’s platform technology and launched their breakthrough product ‘Tropon’ globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia’s leading medical device commercialisation success stories.

### **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision’s current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

## **Inherent risks of Investment in Medical Device development Companies**

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.